{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:46Z","timestamp":1794018586093,"version":"4.8.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016255","name":"INOVIO Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016255","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.mam.2023.101224","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T13:50:31Z","timestamp":1699105831000},"page":"101224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Vaccines for HPV-associated diseases"],"prefix":"10.1016","volume":"94","author":[{"given":"Jeffrey M.","family":"Skolnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mam.2023.101224_bib1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-18-1763","article-title":"Immunotherapy targeting HPV16\/18 generates potent immune responses in HPV-associated head and neck cancer","volume":"25","author":"Aggarwal","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.mam.2023.101224_bib2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/1078-0432.CCR-22-1987","article-title":"Safety and efficacy of MEDI0457 plus durvalumab in patients with human papillomavirus-associated recurrent\/metastatic head and neck squamous cell carcinoma","volume":"29","author":"Aggarwal","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.mam.2023.101224_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/jmv.22111","article-title":"Analyses of human papillomavirus genotypes and viral loads in anogenital warts","volume":"83","author":"Ball","year":"2011","journal-title":"J. Med. Virol."},{"issue":"10","key":"10.1016\/j.mam.2023.101224_bib4","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.3390\/v13101892","article-title":"The not-so-good, the bad and the ugly: HPV E5, E6 and E7 oncoproteins in the orchestration of carcinogenesis","volume":"13","author":"Basukala","year":"2021","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.mam.2023.101224_bib5","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/cncr.30588","article-title":"Human papillomavirus in cervical cancer and oropharyngeal cancer: one cause, two diseases","volume":"123","author":"Berman","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.mam.2023.101224_bib6","first-page":"9","article-title":"Preliminary results of a phase 2 study of VGX-3100 for the treatment of HPV16 and\/or HPV18 (HPV16\/18) related anal HSIL (Poster #000891)","volume":"25","author":"Bhatt","year":"2021","journal-title":"J. Low. Genit. Tract Dis."},{"key":"10.1016\/j.mam.2023.101224_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.977933","article-title":"Governing HPV-related carcinoma using vaccines: bottlenecks and breakthroughs","volume":"12","author":"Bhattacharjee","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.mam.2023.101224_bib8","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1080\/21645515.2020.1823778","article-title":"Durability of response to VGX-3100 treatment of HPV16\/18 positive cervical HSIL","volume":"17","author":"Bhuyan","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.mam.2023.101224_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging concepts and technologies in vaccine development","volume":"11","author":"Brisse","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.mam.2023.101224_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1586\/14760584.2015.990890","article-title":"Electroporation-enhanced delivery of nucleic acid vaccines","volume":"14","author":"Broderick","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.mam.2023.101224_bib11","article-title":"ICO\/IARC information centre on HPV and cancer (HPV information centre)","author":"Bruni","year":"2023","journal-title":"Human Papillomavirus Related Dis. World. Summary Report"},{"issue":"12","key":"10.1016\/j.mam.2023.101224_bib12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.mam.2023.101224_bib13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.mam.2023.101224_bib14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/hum.2017.197","article-title":"Therapeutic DNA vaccines for human papillomavirus and associated diseases","volume":"29","author":"Cheng","year":"2018","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.mam.2023.101224_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The estimated lifetime probability of acquiring human papillomavirus in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex. Transm. Dis."},{"issue":"7","key":"10.1016\/j.mam.2023.101224_bib16","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3","volume":"26","author":"Choi","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.mam.2023.101224_bib17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.55489\/njcm.140920233171","article-title":"Covid-19 vaccine booster dose and the Indian scenario: when we will have a fully immunized population?","volume":"14","author":"Datta","year":"2023","journal-title":"National J. Commun. Med."},{"issue":"4","key":"10.1016\/j.mam.2023.101224_bib18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.mam.2023.101224_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijporl.2009.09.004","article-title":"The role of HPV type in recurrent respiratory papillomatosis","volume":"74","author":"Donne","year":"2010","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"issue":"1\u20132","key":"10.1016\/j.mam.2023.101224_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virol.2013.07.008","article-title":"The E4 protein; structure, function and patterns of expression","volume":"445","author":"Doorbar","year":"2013","journal-title":"Virology"},{"issue":"Suppl. 1","key":"10.1016\/j.mam.2023.101224_bib21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/rmv.1822","article-title":"Human papillomavirus molecular biology and disease association","volume":"25","author":"Doorbar","year":"2015","journal-title":"Rev. Med. Virol."},{"issue":"Suppl. 5","key":"10.1016\/j.mam.2023.101224_bib22","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2023.101224_bib23","series-title":"International Papillomavirus Conference","first-page":"15","article-title":"VGX-3100 for treatment of HPV16\/18-related cervical HSIL: results from a Phase 3 study (Oral abstract #233)","author":"Einstein","year":"2021"},{"issue":"9","key":"10.1016\/j.mam.2023.101224_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146956","article-title":"Vaccines for immunoprevention of cancer","volume":"131","author":"Enokida","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"10316","key":"10.1016\/j.mam.2023.101224_bib25","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mam.2023.101224_bib26","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1186\/s12889-020-09570-z","article-title":"Prevalence and genotype distribution of genital human papillomavirus infection in female sex workers in the world: a systematic review and meta-analysis","volume":"20","author":"Farahmand","year":"2020","journal-title":"BMC Publ. Health"},{"key":"10.1016\/j.mam.2023.101224_bib27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fimmu.2013.00354","article-title":"Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants","volume":"4","author":"Flingai","year":"2013","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.mam.2023.101224_bib28","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1080\/21645515.2021.1893036","article-title":"ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer","volume":"17","author":"Galicia-Carmona","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.mam.2023.101224_bib29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fimmu.2020.00188","article-title":"The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease","volume":"11","author":"Garbuglia","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.mam.2023.101224_bib30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Garc\u00eda-Hern\u00e1ndez","year":"2006","journal-title":"Cancer Gene Ther."},{"issue":"17","key":"10.1016\/j.mam.2023.101224_bib31","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1042\/CS20160786","article-title":"The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review","volume":"131","author":"Graham","year":"2017","journal-title":"Clin. Sci. (Lond.)"},{"issue":"3","key":"10.1016\/j.mam.2023.101224_bib32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijrobp.2020.02.031","article-title":"A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6\/E7 oncogenes after chemoradiation for cervical cancer","volume":"107","author":"Hasan","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.mam.2023.101224_bib33","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.mam.2023.101224_bib34","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-22-1927","article-title":"A therapeutic antigen-presenting cell-targeting DNA vaccine VB10.16 in HPV16-positive high-grade cervical intraepithelial neoplasia: results from a phase I\/IIa trial","volume":"28","author":"Hillemanns","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.mam.2023.101224_bib35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","article-title":"Comparison of DNA and mRNA vaccines against cancer","volume":"25","author":"Jahanafrooz","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.mam.2023.101224_bib36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/vaccines9121413","article-title":"Human papillomavirus vaccine efficacy and effectiveness against cancer","volume":"9","author":"Kamolratanakul","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"10332","key":"10.1016\/j.mam.2023.101224_bib37","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.mam.2023.101224_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.552028","article-title":"Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation","volume":"8","author":"Kombe Kombe","year":"2021","journal-title":"Front. Public Health"},{"issue":"11","key":"10.1016\/j.mam.2023.101224_bib39","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1158\/1055-9965.EPI-21-0733","article-title":"Disparities in healthcare providers' recommendation of HPV vaccination for U.S. Adolescents: a systematic review","volume":"30","author":"Kong","year":"2021","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.mam.2023.101224_bib40","doi-asserted-by":"crossref","first-page":"V494","DOI":"10.1093\/annonc\/mdz253.036","article-title":"Phase Ib\/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent\/metastatic (R\/M) HPV-16+ cancers","volume":"30","author":"Le Tourneau","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.mam.2023.101224_bib41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/vaccines11020280","article-title":"Improved DNA vaccine delivery with needle-free injection systems","volume":"11","author":"Ledesma-Feliciano","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"4\u20136","key":"10.1016\/j.mam.2023.101224_bib42","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000053993","article-title":"Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice","volume":"43","author":"Ledwith","year":"2000","journal-title":"Intervirology"},{"issue":"12","key":"10.1016\/j.mam.2023.101224_bib43","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/DCR.0000000000001219","article-title":"What is the risk of anal carcinoma in patients with anal intraepithelial neoplasia III?","volume":"61","author":"Lee","year":"2018","journal-title":"Dis. Colon Rectum"},{"issue":"3","key":"10.1016\/j.mam.2023.101224_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev. Vaccines"},{"issue":"2","key":"10.1016\/j.mam.2023.101224_bib45","article-title":"A comparison of plasmid DNA and mRNA as vaccine technologies","volume":"7","author":"Liu","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"10.1016\/j.mam.2023.101224_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091861","article-title":"Plasmid DNA for therapeutic applications in cancer","volume":"14","author":"Mart\u00ednez-Puente","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.mam.2023.101224_bib47","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/lary.30749","article-title":"Interim results of a phase 1\/2 open-label study of INO-3107 for HPV-6 and\/or HPV-11\u2013associated recurrent respiratory papillomatosis","volume":"133","author":"Mau","year":"2023","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1016\/j.mam.2023.101224_bib48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.mam.2023.101224_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.2016007","article-title":"Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States","volume":"18","author":"Meites","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.mam.2023.101224_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.909223","article-title":"Prophylactic and therapeutic HPV vaccines: current scenario and perspectives","volume":"12","author":"Mo","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.mam.2023.101224_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.25","article-title":"Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100","volume":"3","author":"Morrow","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"10.1016\/j.mam.2023.101224_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fvl.14.99","article-title":"Human papillomavirus E5 oncoprotein: function and potential target for antiviral therapeutics","volume":"10","author":"M\u00fcller","year":"2015","journal-title":"Future Virol."},{"key":"10.1016\/j.mam.2023.101224_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1749-6632.1995.tb44729.x","article-title":"Potential DNA vaccine integration into host cell genome","volume":"772","author":"Nichols","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.mam.2023.101224_bib54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/infdis\/jiq021","article-title":"Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study","volume":"203","author":"Nyitray","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.mam.2023.101224_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099114","article-title":"Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia","volume":"9","author":"Omland","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mam.2023.101224_bib56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3892\/etm.2020.9316","article-title":"Non-sexual HPV transmission and role of vaccination for a better future","volume":"20","author":"Petca","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.mam.2023.101224_bib57","first-page":"11","article-title":"Preliminary phase 2 efficacy results of VGX-3100 for treatment of HPV-16 and\/or 18 (HPV16\/18) associated vulvar HSIL (Poster #000941)","volume":"25 (2S)","author":"Petrellis","year":"2021","journal-title":"J. Low. Genit. Tract Dis."},{"issue":"11","key":"10.1016\/j.mam.2023.101224_bib58","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.mam.2023.101224_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.633776","article-title":"A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications","volume":"9","author":"Qin","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.mam.2023.101224_bib60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.gt.3301117","article-title":"The promise of nucleic acid vaccines","volume":"7","author":"Restifo","year":"2000","journal-title":"Gene Ther."},{"issue":"10","key":"10.1016\/j.mam.2023.101224_bib61","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.3390\/ijerph15102210","article-title":"Prevalence and risk factors of human papillomavirus in male patients: a systematic review and meta-analysis","volume":"15","author":"Rodr\u00edguez-\u00c1lvarez","year":"2018","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"3","key":"10.1016\/j.mam.2023.101224_bib62","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s11864-023-01050-x","article-title":"Immunotherapy in HPV-related oropharyngeal cancers","volume":"24","author":"Roof","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"issue":"12","key":"10.1016\/j.mam.2023.101224_bib63","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.mam.2023.101224_bib64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.mam.2023.101224_bib65","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001540","article-title":"The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation","volume":"102","author":"Scarth","year":"2021","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.mam.2023.101224_bib66","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results","volume":"26","author":"Schiller","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.mam.2023.101224_bib67","article-title":"A brief review on DNA vaccines in the era of COVID-19","author":"Shafaati","year":"2021","journal-title":"Future Virol"},{"key":"10.1016\/j.mam.2023.101224_bib68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ctrv.2019.07.001","article-title":"The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer","volume":"78","author":"Shibata","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.mam.2023.101224_bib69","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/ITT.S273327","article-title":"Therapeutic vaccines for HPV-associated malignancies","volume":"9","author":"Smalley Rumfield","year":"2020","journal-title":"ImmunoTargets Ther."},{"issue":"6","key":"10.1016\/j.mam.2023.101224_bib70","first-page":"1","article-title":"Vaccines for the prevention of human papillomavirus infections","volume":"11","author":"Speck","year":"2006","journal-title":"Skin Therapy Lett"},{"issue":"12","key":"10.1016\/j.mam.2023.101224_bib71","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"issue":"2","key":"10.1016\/j.mam.2023.101224_bib72","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/v14020239","article-title":"Therapeutic DNA vaccines against HPV-related malignancies: promising leads from clinical trials","volume":"14","author":"Tang","year":"2022","journal-title":"Viruses"},{"issue":"7\u20138","key":"10.1016\/j.mam.2023.101224_bib73","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1080\/21645515.2019.1600985","article-title":"HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection","volume":"15","author":"Timbang","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"issue":"10008","key":"10.1016\/j.mam.2023.101224_bib74","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.mam.2023.101224_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114142","article-title":"Toward rational vaccine engineering","volume":"183","author":"Vishweshwaraiah","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.mam.2023.101224_bib77","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1080\/14760584.2022.2129615","article-title":"Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review","volume":"21","author":"Wang","year":"2022","journal-title":"Expert Rev. Vaccines"},{"issue":"1","key":"10.1016\/j.mam.2023.101224_bib78","doi-asserted-by":"crossref","first-page":"e2337","DOI":"10.1002\/rmv.2337","article-title":"Transmission and clearance of human papillomavirus infection in the oral cavity and its role in oropharyngeal carcinoma - a review","volume":"33","author":"Wierzbicka","year":"2023","journal-title":"Rev. Med. Virol."},{"issue":"4","key":"10.1016\/j.mam.2023.101224_bib79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.biotechadv.2009.02.003","article-title":"Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production","volume":"27","author":"Williams","year":"2009","journal-title":"Biotechnol. Adv."},{"issue":"50","key":"10.1016\/j.mam.2023.101224_bib80","first-page":"645","article-title":"Human papillomavirus vaccines: WHO position paper (2022 update)","volume":"97","author":"World Health Organization","year":"2022","journal-title":"Wkly. Epidemiol. Rec."},{"issue":"1","key":"10.1016\/j.mam.2023.101224_bib81","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s40136-023-00443-8","article-title":"Therapeutic vaccination for HPV-mediated cancers","volume":"11","author":"Yan","year":"2023","journal-title":"Curr Otorhinolaryngol Rep"},{"issue":"1","key":"10.1016\/j.mam.2023.101224_bib82","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-016-0293-9","article-title":"Perspectives for therapeutic HPV vaccine development","volume":"23","author":"Yang","year":"2016","journal-title":"J. Biomed. Sci."},{"issue":"12","key":"10.1016\/j.mam.2023.101224_bib83","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.mam.2023.101224_bib84","first-page":"52","article-title":"The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC","volume":"8","author":"Yusupov","year":"2019","journal-title":"Am J Stem Cells"},{"key":"10.1016\/j.mam.2023.101224_bib75","unstructured":"GARDASIL 9 [Package Insert]. Rahway, NJ: Merck Sharp & Dohme LLC; 2023."}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009829972300064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009829972300064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:28:57Z","timestamp":1789676937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009829972300064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":84,"alternative-id":["S009829972300064X"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2023.101224","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccines for HPV-associated diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Aspects of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mam.2023.101224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101224"}}